COVID-19 Vaccine Hesitancy-A Scoping Review of Literature in High-Income Countries.
Aw J, Seng JJB, Seah SSY, Low LL. · 2021
Read COVID-19 Vaccine Hesitancy-A Scoping Review of Literature in High-Income Countries. by Aw J, Seng JJB, Seah SSY, Low LL. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8402587.txt.
Introduction
Aw and co-authors scope the research on COVID-19 vaccine hesitancy in high-income countries. Hesitancy is a key barrier to vaccine uptake in these settings. The review gathers rates and the factors tied to them, with the search current as of March 2021.
Of 2237 articles found, 97 were included. Most studies came from the United States, with Italy next. Reported hesitancy rates ranged widely, from 7 percent to near 78 percent. Younger age, female sex, and lower education linked to more hesitancy. So did low felt risk of catching COVID-19 and no recent flu shot. The authors sort the factors into vaccine, personal, group, and context themes.
Catalog record
| CREATOR | Aw J, Seng JJB, Seah SSY, Low LL. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
COVID-19 Vaccine Hesitancy—A Scoping Review of Literature in High-Income Countries By Junjie Aw, Jun Jie Benjamin Seng, Sharna Si Ying Seah, Lian Leng Low, Barbara Rath, Ger Rijkers Published in: Vaccines DOI: 10.3390/vaccines9080900 ABSTRACT Vaccine hesitancy forms a critical barrier to the uptake of COVID-19 vaccine in high-income countries or regions. This review aims to summarize rates of COVID-19 hesitancy and its determinants in high-income countries or regions. A scoping review was conducted in Medline®, Embase®, CINAHL®, and Scopus® and was reported in accordance with the PRISMA-SCr checklist. The search was current as of March 2021. Studies which evaluated COVID-19 vaccine hesitancy and its determinants in high-income countries (US$12,536 or more GNI per capita in 2019) were included. Studies conducted in low, lower-middle, and upper-middle income countries or regions were excluded. Factors associated with vaccine hesitancy were grouped into four themes (vaccine specific, individual, group, or contextual related factors). Of 2237 articles retrieved, 97 articles were included in this review. Most studies were conducted in U.S. (n = 39) and Italy (n = 9). The rates of vaccine hesitancy across high-income countries or regions ranged from 7–77.9%. 46 studies (47.4%) had rates of 30% and more. Younger age, females, not being of white ethnicity and lower education were common contextual factors associated with increased vaccine hesitancy. Lack of recent history of influenza vaccination, lower self-perceived risk of contracting COVID-19, lesser fear of COVID-19, believing that COVID-19 is not severe and not having chronic medical conditions were most frequently studied individual/group factors associated with increased vaccine hesitancy. Common vaccine-specific factors associated with increased vaccine hesitancy included beliefs that vaccine are not safe/effective and increased concerns about rapid development of COVID-19 vaccines. Given the heterogeneity in vaccine hesitancy definitions used across studies, there is a need for standardization in its assessment. This review has summarized COVID-19 vaccine hesitancy determinants that national policymakers can use when formulating health policies related to COVID-19 vaccination. 1. INTRODUCTION Since its first reported case in December 2019, the coronavirus-2019 (COVID-19) pandemic has culminated in nearly 179 million infections and 3.88 million deaths globally as of 24 June 2021 [1]. Lockdowns, social distancing measures, and movement restrictions were implemented as a result to abate the spread of infection worldwide [2]. The aftermath of the pandemic has negatively affected global economies. For example, the Internal Labor Organization has estimated 25 million jobs to be lost and the United Nations World Tourism Organization has estimated a loss of US$80 billion dollars in international travel receipts internationally in 2020 [3,4]. Vaccination forms a critical pillar in the road to recovery from the COVID-19 pandemic [5]. Notably, vaccine candidates with promising results received expeditious emergency use authorization by drug authorities. Despite quick and concerted vaccination programs implemented by governments globally, such efforts have been hampered by vaccine hesitancy. Vaccine hesitancy was identified by the World Health Organization as one of the 10 threats to global health in 2019. It is defined as the “delay in acceptance or refusal of vaccination despite availability of vaccination services” by the Strategic Advisory Group of Experts on immunization and involves a complex interaction of time, place, context, and vaccine specific factors [6]. Among non-high income countries or regions, results from the 2018 Wellcome Global monitor survey showed that vaccines were widely accepted [7,8], in contrast to high-income countries (defined by World Bank as countries having a 2019 Gross National Income (GNI) per capita of US$12,536 and more) [9]. A recent study by Arce et al. showed that the average willingness to take COVID-19 vaccine was higher in the populace from non-high income countries or regions such as Nepal (97%) as compared to those in high-income countries or regions such as United States (6%) [10]. Similar findings were noted in a study by Sallam et al. [11]. In view of the importance of COVID-19 vaccine hesitancy, we aim to perform a scoping review to evaluate COVID-19 vaccine hesitancy and its determinants among high-income countries or regions. We hope that our results will aid healthcare administrators and policymakers in understanding COVID-19 vaccine hesitancy determinants in high-income countries or regions. This will, in turn, aid and facilitate the planning of vaccination campaigns to enhance uptake of COVID-19 vaccinations. 2. METHODOLOGY We conducted a scoping review on studies which evaluated COVID-19 vaccine hesitancy in high-income countries or regions. This review was reported using the Preferred Reporting Items for Systematic review and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) checklist [12]. 2.1. Protocol and Registration The protocol for this scoping review is registered on 11 April 2021 on Open Science Framework (Available online: https://osf.io/3n7yv (accessed on 11 April 2021)). 2.2. Eligibility Criteria and Information Sources A literature search was performed in four major literature databases which were namely: Medline®, Embase®, CINAHL®, and Scopus®. Full-text articles in English language which evaluated COVID-19 hesitancy rates and the associated determinants in high-income countries or regions were included. Study designs in this review included randomized controlled trials, observational studies, cross-sectional studies, cohort studies and qualitative studies. We excluded studies that were performed in non-high-income countries (GNI per capita < US$12,535). Commentaries, editorials, letters and correspondences without original data as well as irrelevant systematic reviews and meta-analyses were excluded. The search period for the review spanned between December 2019 and March 2021. Institutional review board approval was exempted for this review as it did not involve human subjects. 2.3. Search Strategy The search strategy comprised of two main themes which were COVID-19 vaccine and vaccine hesitancy. The search strategy used was adapted from prior systematic reviews which evaluated vaccine hesitancy related to other vaccines [13,14,15]. The full details of the search strategy is available from Supplementary File Table S1. 2.4. Selection of Sources of Evidence, Data Charting Process, and Data Items Citations retrieved from the four databases were exported into Endnote Software Online (Clarivate Analytics, Philadelphia, PA, USA). Duplicated citations were removed prior to screening of articles. Two independent reviewers (J Aw and JJB Seng performed the initial pilot exercise for the screening of the first 200 records (based on title and abstract). Thereafter, the titles and abstracts of all retrieved articles from the four databases were screened by the same reviewers independently. The full-text articles of potentially relevant articles were evaluated prior to inclusion in this review. All disagreements in the inclusion phase of the review were discussed to reach a consensus. For discrepancies which could not be resolved between the two reviewers, arbitration was made with a third independent reviewer (SYS SEAH). To chart data from the included articles, a standardized Microsoft Excel data collection sheet was used. This information included the name of author, title of study, publication year, sample size, study design and methodology, characteristics of patient population, tools used to evaluate COVID-19 vaccine hesitancy, reported hesitancy rates, and determinants associated with increased COVID-19 vaccine hesitancy. 2.5. Critical Appraisal of Individual Sources of Evidence The risk of bias appraisal for included studies was not performed as this was not the objective of this scoping review. 2.6. Summary and Synthesis of Results Descriptive statistics were used to summarize the characteristics of studies included in this review. Vaccine hesitancy rate was reported from individual study according to the definition described in each study. In studies